The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease

Phase 2CompletedNCT00163085

Pfizer12 enrolled

Overview

To determine the effects of the NMDA antagonist, CP-101,606, in subjects with Parkinson's Disease

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Parkinson's Disease

Interventions

NR2B NMDA Antagonist CP-101,606 (traxoprodil)DRUG

Eligibility

Sex: ALLMin age: 30 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 30- 80-year-old PD patients (UK Parkinson's Disease Brain Bank criteria) with a Hoehn \& Yahr stage score of 2-5 in the "off" state. Exclusion Criteria: * Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).

Locations (1)

Pfizer Investigational Site

Portland, Oregon, United States

Outcomes

Primary Outcomes

Dyskinesia Rating Scale

Secondary Outcomes

Fingertapping

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.